Literature DB >> 23328481

Suppression of miRNA-708 by polycomb group promotes metastases by calcium-induced cell migration.

Seongho Ryu1, Kevin McDonnell, Hyejin Choi, Dingcheng Gao, Mary Hahn, Natasha Joshi, Sun-Mi Park, Raul Catena, Yoonkyung Do, Jacqueline Brazin, Linda T Vahdat, Randi B Silver, Vivek Mittal.   

Abstract

The progression of cancer to metastatic disease is a major cause of death. We identified miR-708 being transcriptionally repressed by polycomb repressor complex 2-induced H3K27 trimethylation in metastatic breast cancer. miR-708 targets the endoplasmic reticulum protein neuronatin to decrease intracellular calcium level, resulting in reduction of activation of ERK and FAK, decreased cell migration, and impaired metastases. Ectopic expression of neuronatin refractory to suppression by miR-708 rescued cell migration and metastasis defects. In patients with breast cancer, miR-708 expression was decreased in lymph node and distal metastases, suggesting a metastasis-suppressive role. Our findings uncover a mechanistic role for miR-708 in metastasis and provide a rationale for developing miR-708 as a therapeutic agent against metastatic breast cancer.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23328481     DOI: 10.1016/j.ccr.2012.11.019

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  64 in total

Review 1.  Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes.

Authors:  Sasagu Kurozumi; Yuri Yamaguchi; Masafumi Kurosumi; Miki Ohira; Hiroshi Matsumoto; Jun Horiguchi
Journal:  J Hum Genet       Date:  2016-07-21       Impact factor: 3.172

Review 2.  Tumor metastasis: moving new biological insights into the clinic.

Authors:  Liling Wan; Klaus Pantel; Yibin Kang
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

3.  MicroRNA-4417 is a tumor suppressor and prognostic biomarker for triple-negative breast cancer.

Authors:  Chen Khuan Wong; Christopher Gromisch; Sait Ozturk; Panagiotis Papageorgis; Hamid Mostafavi Abdolmaleky; Björn M Reinhard; Arunthathi Thiagalingam; Sam Thiagalingam
Journal:  Cancer Biol Ther       Date:  2019-03-28       Impact factor: 4.742

4.  Effects of microRNA-708 on Epithelial-Mesenchymal Transition, Cell Proliferation and Apoptosis in Melanoma Cells by Targeting LEF1 through the Wnt Signaling Pathway.

Authors:  Xiao-Fei Song; Qi-Hua Wang; Ran Huo
Journal:  Pathol Oncol Res       Date:  2017-11-14       Impact factor: 3.201

Review 5.  Non-coding RNA networks in cancer.

Authors:  Eleni Anastasiadou; Leni S Jacob; Frank J Slack
Journal:  Nat Rev Cancer       Date:  2017-11-24       Impact factor: 60.716

6.  microRNA Expression in Prospectively Collected Blood as a Potential Biomarker of Breast Cancer Risk in the BCFR.

Authors:  Chin-Wen Chang; Hui-Chen Wu; Mary Beth Terry; Regina M Santella
Journal:  Anticancer Res       Date:  2015-07       Impact factor: 2.480

7.  RASAL2 activates RAC1 to promote triple-negative breast cancer progression.

Authors:  Min Feng; Yi Bao; Zhimei Li; Juntao Li; Min Gong; Stella Lam; Jinhua Wang; Diego M Marzese; Nicholas Donovan; Ern Yu Tan; Dave S B Hoon; Qiang Yu
Journal:  J Clin Invest       Date:  2014-11-10       Impact factor: 14.808

Review 8.  PERK Integrates Oncogenic Signaling and Cell Survival During Cancer Development.

Authors:  Yiwen Bu; J Alan Diehl
Journal:  J Cell Physiol       Date:  2016-03-06       Impact factor: 6.384

9.  Inhibition of KPNA4 attenuates prostate cancer metastasis.

Authors:  J Yang; C Lu; J Wei; Y Guo; W Liu; L Luo; G Fisch; X Li
Journal:  Oncogene       Date:  2016-12-12       Impact factor: 9.867

10.  MiR-654-5p attenuates breast cancer progression by targeting EPSTI1.

Authors:  Yu-Yan Tan; Xiao-Yun Xu; Jin-Feng Wang; Cheng-Wu Zhang; Sheng-Chu Zhang
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.